SCHEMBL4323686

SCHEMBL4323686

Cc1ccc(F)c(-c2cc(C(=O)O)no2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
RARA P10276 2/20 0.47
RXRA P19793 2/20 0.47
HTT P42858 1/20 0.47
RXRG P48443 1/20 0.47
PTPN1 P18031 3/20 0.46
HPGD P15428 2/20 0.46
MAPT P10636 1/20 0.46
RECQL P46063 1/20 0.46
SLC9A1 P19634 1/20 0.45
BRD4 O60885 1/20 0.45
NPC1 O15118 5/20 0.44
RAB9A P51151 3/20 0.44
CDH1 P12830 1/20 0.43
CTNNB1 P35222 1/20 0.43
TCF7L2 Q9NQB0 1/20 0.43
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5958371 0.88 SLC9A1 (0.45) ALDH1A1HPGDMAPTSLC9A1NPC1
SCHEMBL1544585 0.84 TP53 (0.51) ALDH1A1PTPN1HPGDMAPTSLC9A1
SCHEMBL5958449 0.84 SLC9A1 (0.42) ALDH1A1HTTPTPN1HPGDSLC9A1
SCHEMBL27788542 0.80 MAPT (0.44) ALDH1A1MAPTSLC9A1NPC1RAB9A
SCHEMBL70022 0.80 ALDH1A1 (0.62) ALDH1A1PTPN1HPGDMAPTRECQL
SCHEMBL29775661 0.78 ALDH1A1 (0.51) ALDH1A1RARARXRAHTTRXRG
SCHEMBL19815117 0.78 ALDH1A1 (0.51) ALDH1A1RARARXRAHTTRXRG
SCHEMBL27788541 0.77 SLC9A1 (0.41) ALDH1A1MAPTSLC9A1NPC1RAB9A
SCHEMBL6195123 0.77 SLC9A1 (0.41) MAPTSLC9A1NPC1RAB9AMEN1
SCHEMBL5958357 0.76 NPC1 (0.41) ALDH1A1PTPN1HPGDMAPTSLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585881-B2 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2009-09-08 US disclosed
US-20080045571-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-02-21 US disclosed
US-20080015204-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-01-17 US disclosed
US-20080015234-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2008-01-17 US disclosed
US-20070293545-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2007-12-20 US disclosed
US-20070179188-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-02 US disclosed
US-20050272779-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015234-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS GRM5, GRIK5, GRM2 ALDH1A1 3875/4885RARA 3089/4885RXRA 924/4885
US-20070179188-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists GRM5, GRIK5, GRM2 ALDH1A1 4066/4885RARA 3269/4885RXRA 1083/4885
US-20050272779-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists GRM5, GRIK5, GRM2 ALDH1A1 3875/4885RARA 3089/4885RXRA 924/4885
US-20080045571-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS GRM5, GRIK5, GRM2 ALDH1A1 3875/4885RARA 3089/4885RXRA 924/4885
US-20070293545-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS GRM5, GRIK5, GRM2 ALDH1A1 3875/4885RARA 3089/4885RXRA 924/4885
US-20080015204-A1 ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS GRM5, GRIK5, GRM2 ALDH1A1 3875/4885RARA 3089/4885RXRA 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.